(TPST) Tempest Therapeutics, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TPST) Tempest Therapeutics, Inc. Complete Analysis Pack
Don't Miss the Bigger Picture
This Tempest Therapeutics, Inc. Porter's Five Forces Analysis helps you evaluate the competitive pressures shaping the company’s market position, from rivalry to buyer and supplier power. The page already shows a real preview of the report, so you can review the actual content before buying. Get the full version for the complete ready-to-use analysis.
Suppliers Bargaining Power
Specialized API providers
Tempest Therapeutics, Inc. relies on specialized manufacturers for small-molecule active ingredients and trial materials. In early-stage oncology, only a small pool of GMP-qualified suppliers can meet quality and regulatory rules, so those vendors can press on cost, lead times, and capacity. That makes supplier power high, because any API delay can slow trial starts and data readouts.
Contract research organizations
Tempest Therapeutics, Inc. is a clinical-stage biotech with no product revenue in 2025, so it depends on CROs for trial runs, data work, and regulatory support. Oncology CRO work is concentrated in a few experienced providers, and specialized trial services can be costly and hard to replace. That gives suppliers more pricing power, especially when Tempest needs fast turnaround or niche expertise.
Analytical and testing labs
Analytical and testing labs have strong leverage over Tempest Therapeutics because preclinical and clinical work needs GLP and GCP-grade bioanalytical, toxicology, and stability testing. That pool is narrow, so delays or vendor changes can slow studies and raise switching costs. In 2025, Tempest still depended on outside labs for these regulated services, which leaves less room to push prices down.
Clinical site networks
Hospitals and cancer centers have high supplier power for Tempest Therapeutics, Inc. because they control patient access and trial enrollment. In oncology, especially for novel mechanisms and rare segments, elite sites can pick studies, so slow start-up or weak enrollment can push timelines by months and raise development risk.
Tempest Therapeutics, Inc. depends on a concentrated pool of qualified sites, so each added site matters. If a key cancer center delays activation or enrollment, the company’s burn rate and readout timing can move fast, which makes clinical site networks a material bargaining force.
- Sites control access to eligible patients.
- Top oncology centers can be selective.
- Enrollment speed drives trial timelines.
- Delays can lift cash burn and risk.
Intellectual property licensors
Tempest Therapeutics, Inc. is a clinical-stage biotech, so any licensed science, tools, or platform can give intellectual property licensors real leverage over economics and strategy. Those deals often carry upfront fees, milestone payments, royalties, and field limits, which can raise trial costs and narrow Tempest Therapeutics, Inc.'s options. In a capital-heavy model with no product revenue yet, even one key license can shape pipeline speed and partner terms.
- Licensors can set royalties and milestones.
- Field limits can restrict pipeline use.
- Key licenses can slow or raise costs.
Tempest Therapeutics Faces High Supplier Power in 2025
Tempest Therapeutics, Inc. faces high supplier power in 2025 because it depends on GMP manufacturers, CROs, GLP/GCP labs, and selective oncology sites; each can delay trials and raise costs. With no product revenue in 2025, Tempest Therapeutics, Inc. has limited leverage on pricing or terms, so vendor concentration matters more.
| Supplier | Power | Impact |
|---|---|---|
| GMP/API | High | Delay trials |
| CROs/labs | High | Raise spend |
What is included in the product
Detailed Word Document
Tailored for Tempest Therapeutics, Inc., this analysis examines competitive pressures shaping pricing, profitability, and strategic risk.
Customizable Excel Spreadsheet
A quick, board-ready view of Tempest Therapeutics’ five competitive forces—ideal for fast strategy calls.
Reference Sources
Gives a traceable source trail for Tempest Therapeutics, Inc., helping users verify claims fast and make decisions with greater confidence.
Customers Bargaining Power
Patients have low direct power
Patients have low direct power because Tempest Therapeutics, Inc. medicines are bought through physicians and payers, not by end users. In 2025 and 2026, that meant adoption still hinged on clinical data, FDA status, and reimbursement, while Tempest had no approved commercial oncology drug to negotiate with patients. So patient price pressure stays limited.
Oncologists drive treatment choice
Oncologists and cancer centers decide if a therapy gets used, so their indirect power is high. In crowded solid tumors, they want better efficacy, safety, and dosing convenience than the standard of care. With about 20 million new cancer cases worldwide in 2022, even small shifts in physician preference can move demand fast.
Payers control access
Commercial insurers and government payers can decide if Tempest Therapeutics' future therapy gets reimbursed, and they can demand prior auth, price cuts, and proof of cost-effectiveness. U.S. Medicare and Medicaid cover about 160 million people, so payer rules can shape most launch access. For a biotech with no product revenue today, payer power can be very high after approval.
Large pharma partners can negotiate hard
Large pharma partners can push hard on Tempest Therapeutics, Inc. deals because they bring scale, sales reach, and trial budgets. Tempest already had only 1 lead asset in late-stage focus, so a partner can demand deeper proof before paying up.
That matters in licensing and co-development: big buyers often wait for clear efficacy data, not just early signals, before pricing a deal. In biotech, weak cash leverage can also force smaller firms to accept lower upfront cash and heavier milestone-based terms.
- Big pharma has stronger negotiating leverage.
- Tempest needs strong data to win better terms.
- Milestones can replace upfront cash.
Clinical trial participants are selective
Clinical trial participants are selective because eligible oncology patients often can choose among several studies at major centers, and 2025 U.S. cancer incidence is projected at about 2.0 million new cases, keeping trial pools competitive. Tempest must sell a strong protocol, quick site start-up, and patient-friendly visits to win enrollments. That lifts customer power in the clinical-stage phase.
- Multiple trial choices raise patient leverage
- Better sites and support drive enrollment
- Competition is strongest at top cancer centers
Tempest Faces Strong Buyer Leverage From Payers, Doctors, and Partners
Customer bargaining power is high for Tempest Therapeutics, Inc. because payers, oncologists, and pharma partners can block adoption or force price and deal concessions. With U.S. Medicare and Medicaid covering about 160 million people and 2025 U.S. cancer incidence near 2.0 million new cases, reimbursement and physician choice matter more than patient demand. Tempest's no-revenue, clinical-stage profile keeps buyer leverage strong.
| Buyer | Power | Why it matters |
|---|---|---|
| Payers | High | Access and price control |
| Oncologists | High | Drive prescribing |
| Pharma partners | High | Set deal terms |
Same Document Delivered
Tempest Therapeutics, Inc. Porter's Five Forces Analysis
This preview shows the exact Tempest Therapeutics, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no mockups, no placeholders, just the finished document. It’s professionally formatted and ready to use immediately upon download. What you see here is the same file you’ll get after payment.
Rivalry Among Competitors
Crowded oncology pipeline
Oncology is a $200B+ drug market, so competition is fierce. Hundreds of solid-tumor, immuno-oncology, and novel-pathway programs are chasing the same trial sites, investigators, and investors. For Tempest Therapeutics, Inc., that means each data readout must stand out fast or risk being lost in the crowd.
Similar biology targets
Tempest Therapeutics, Inc. works on EP2/EP4, PPAR alpha, and TREX-1 biology, all of which sit inside crowded tumor-immunology research. That means other biotech firms and Big Pharma can chase the same pathways or close variants, raising direct scientific rivalry. In 2025, Tempest had no approved products and remained a small-cap developer, so pipeline differentiation matters most.
Data-driven differentiation is critical
Tempest Therapeutics, Inc. competes in a crowded oncology field where early-stage assets are judged first on clinical signal, safety, and biomarker logic. In 2025, oncology still led FDA approvals, with 20+ new cancer drugs and label expansions, so weak first-in-human data can quickly cut investor and partner interest. Strong response data and clean safety are what help Tempest stand out among many competing assets.
High capital competition
Tempest Therapeutics, Inc. faces high capital competition because biotech rivals fight for both trial wins and investor cash. In clinical-stage biotech, limited funding can force hard trade-offs: the strongest programs get more capital, while weaker ones can be slowed or cut. That makes financing pressure a direct part of rivalry, not just a back-office issue.
- Biotech competes in labs and capital markets.
- Cash limits narrow pipeline focus.
- Clinical-stage firms feel this most.
Partnership race is intense
Partnership race is intense because strategic collaborations with larger pharma can validate Tempest Therapeutics, Inc.'s platform and fund late-stage work. At the same time, Big Pharma BD teams face a crowded field of 100+ oncology biotechs chasing the same deals, so Tempest needs sharper data and a clear mechanism story to stand out.
That means stronger proof of activity, cleaner biomarker logic, and a deal package that lowers diligence risk. One-liner: in this market, good science is not enough; it has to look partner-ready.
- Large pharma brings money and validation.
- Many biotechs compete for same partners.
- Differentiated data wins better terms.
Tempest Faces Fierce Oncology Competition With No Approved Drugs
Competitive rivalry is high because Tempest Therapeutics, Inc. fights in a crowded oncology field with 2025 FDA cancer approvals and label expansions still above 20, while it has no approved products. Its EP2/EP4, PPAR alpha, and TREX-1 programs face direct pathway rivals, so clinical signal, safety, and biomarker proof must land fast.
| Metric | 2025 |
|---|---|
| FDA cancer approvals | 20+ |
| Tempest approved products | 0 |
| Core pathways | 3 |
Substitutes Threaten
Standard therapies remain strong
Solid tumors already have strong substitutes: surgery, radiation, chemotherapy, and approved targeted agents. In the U.S., the American Cancer Society projected 2.0 million new cancer cases in 2025, so most patients enter care with these standard options already on the table. Tempest Therapeutics, Inc. must show clear added benefit or better tolerability to win use.
That makes substitution pressure high, because doctors can switch to proven regimens if Tempest Therapeutics, Inc. does not outperform them.
Checkpoint and combination regimens
Tempest Therapeutics faces a high substitution threat because approved immuno-oncology combos like nivolumab plus ipilimumab already set a strong bar, and first-line checkpoint regimens kept expanding in 2025. If these standards keep improving, Tempest may have to show clear add-on benefit, not full replacement value. That makes payer and clinician adoption harder, especially in crowded oncology settings.
Other investigational drugs
Tempest Therapeutics, Inc. faces high substitute risk because oncology is crowded: more than 1,000 cancer drugs are in clinical development, and many target the same patient groups. A rival asset with better efficacy, safety, or dosing can replace Tempest Therapeutics, Inc. in trials and later in care. The fast pace of oncology innovation keeps this pressure high.
Biomarker-guided alternatives
Precision oncology is expanding fast: the global biomarker testing market was about $18.2 billion in 2025, and that keeps shifting patients toward matched drugs and away from broad, non-segmented cancer therapies. If Tempest Therapeutics, Inc. cannot show a clear biomarker-linked benefit, oncologists may favor established targeted options with stronger response data, which hurts its differentiation.
- Biomarker fit drives treatment choice.
- Clearer rivals raise substitute risk.
- Weak marker data lowers Tempest Therapeutics, Inc. appeal.
Non-drug care pathways
Non-drug care pathways keep substitution pressure high for Tempest Therapeutics, Inc. In many solid tumors, surgery and local therapy still lead care, and in earlier disease doctors may choose watchful waiting instead of a new drug.
That matters because oncology is huge: the IARC estimated about 20 million new cancer cases worldwide in 2022, and many of those cases still rely on non-systemic options. In later-line disease, palliative care can also reduce the need for another active agent.
- Surgery can replace drug use.
- Local therapy stays preferred in some settings.
- Watchful waiting can delay treatment.
- Palliative care lowers drug dependence.
Tempest Faces High Substitute Pressure in Oncology
Threat of substitutes is high for Tempest Therapeutics, Inc. because oncology already has surgery, radiation, chemotherapy, checkpoint inhibitors, and biomarker-matched drugs. With about 2.0 million U.S. cancer cases projected for 2025 and over 1,000 cancer drugs in development, doctors can switch fast if Tempest Therapeutics, Inc. lacks better efficacy or safety.
| Substitute | Pressure |
|---|---|
| Standard care | High |
| Targeted drugs | High |
| Non-drug care | Medium |
Entrants Threaten
High scientific barriers
Tempest Therapeutics, Inc. faces a low threat from new entrants because oncology drug discovery needs deep biology, medicinal chemistry, and translational expertise. Industry data show only about 1 in 10 oncology candidates that enter clinical testing ever win FDA approval, so most programs fail before proof of concept. That failure rate, plus long trials and high R&D spend, makes entry hard for inexperienced firms.
Regulatory and trial hurdles
New entrants face a 30-day FDA IND review, ethics board checks, and then years of costly oncology trials. Phase 2/3 cancer studies often enroll 100s of patients and can run for 2-5 years, with biomarker testing and safety monitoring adding more cost and delay. Those hurdles keep credible new rivals few.
Capital requirements are large
Clinical-stage oncology is capital heavy: a Phase 1 trial can cost about $4 million to $20 million, Phase 2 about $7 million to $25 million, and Phase 3 often $20 million to $100 million. Tempest Therapeutics also faces long-run spend on manufacturing, trial sites, and FDA/EMA work before any revenue arrives. That cash burn makes entry hard and keeps many rivals out.
IP can slow entry but not stop it
Tempest Therapeutics, Inc. has some protection from patents and trade secrets around its lead science, but that moat is narrow. In biotech, rivals can still build around the same biology with different molecules or mechanisms, so entry barriers slow new firms, but they do not block them.
Tempest Therapeutics, Inc. is still a clinical-stage company with no approved product, so its edge depends on how well its IP protects each program. That makes entry harder, but not impossible, because other developers can spend capital and time to reach the same target through a different route.
- Patents protect specific assets.
- Know-how adds extra friction.
- Alternative molecules can bypass IP.
- Barriers exist, but stay limited.
Biotech startups can still emerge
Biotech startups can still emerge in oncology because fresh science keeps coming out of universities and cancer centers, and venture capital still funds small teams that can turn one strong asset into a company. Shared tools, CRO access, and outsourced manufacturing also mean founders do not need to build a full lab and plant on day one. That keeps Tempest Therapeutics, Inc. facing a moderate threat of new entrants.
- Academic spinouts keep feeding oncology.
- Venture funding still backs novel science.
- CROs and CMOs lower startup costs.
- Entry pressure stays moderate over time.
Tempest Faces Limited New-Entrant Risk in High-Bar Oncology
Tempest Therapeutics, Inc. still faces a low-to-moderate threat from new entrants because oncology entry needs heavy capital, long trials, and rare expertise. Only about 10% of oncology candidates reach FDA approval, while Phase 1, 2, and 3 trials can cost about $4 million-$100 million. Patents help, but rivals can still build around the same biology.
| Barrier | Data |
|---|---|
| FDA approval rate | ~10% |
| Phase 1 cost | $4M-$20M |
| Phase 3 cost | $20M-$100M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.